Ergomed (AIM:ERGO) - Hisse Senedi Fiyatı, Haberler ve Analizler

ERGO Stoklara Genel Bakış

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. Daha fazla detay

ERGO temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	3/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Kazançların yılda 14.17% oranında artması öngörülüyor

Kazançlar geçen yıl 12.3% oranında arttı

Risk Analizi

Son 3 ayda dalgalı hisse senedi fiyatı

Hissedarlar geçen yıl sulandırıldı

Ergomed plc Rakipler

hVIVO

AIM:HVO

UK£155.8m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£193.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Ergomed
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	UK£13.46
52 Haftanın En Yüksek Seviyesi	UK£13.80
52 Haftanın En Düşük Seviyesi	UK£8.95
Beta	0.79
11 Aylık Değişim	0.90%
3 Aylık Değişim	21.26%
1 Yıllık Değişim	3.54%
33 Yıllık Değişim	67.41%
5 Yıllık Değişim	812.54%
Halka arzdan bu yana değişim	728.31%

Son Haberler & Güncellemeler

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Hissedar Getirileri

	ERGO	GB Life Sciences	GB Pazar
7D	0.1%	-10.6%	0.8%
1Y	3.5%	-30.2%	6.6%

Getiri vs. Endüstri: ERGO geçen yıl % -30.2 oranında getiri sağlayan UK Life Sciences sektörünü aştı.

Getiri vs Piyasa: ERGO geçen yıl % 6.6 oranında getiri sağlayan UK Piyasasını aştı.

Fiyat Oynaklığı

Is ERGO's price volatile compared to industry and market?
ERGO volatility
ERGO Average Weekly Movement	8.1%
Life Sciences Industry Average Movement	6.4%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: ERGO hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ERGO 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala UK hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1997	1,400	n/a	www.ergomedplc.com

Ergomed plc Temel Bilgiler Özeti

Ergomed'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ERGO temel i̇stati̇sti̇kler
Piyasa değeri	UK£701.05m
Kazançlar(TTM)	UK£15.00m
Gelir(TTM)	UK£152.09m

46.7x

F/K Oranı

4.6x

P/S Oranı

ERGO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ERGO gelir tablosu (TTM)
Gelir	UK£152.09m
Gelir Maliyeti	UK£68.82m
Brüt Kâr	UK£83.27m
Diğer Giderler	UK£68.27m
Kazançlar	UK£15.00m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.29
Brüt Marj	54.75%
Net Kâr Marjı	9.86%
Borç/Özkaynak Oranı	0%

ERGO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ERGO Stoklara Genel Bakış

Ödüller

Risk Analizi

Ergomed plc Rakipler

AIM:HVO

UK£155.8m

AIM:C4XD

UK£30.3m

LSE:GNS

UK£1.1b

AIM:BVXP

UK£193.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released